Medical expert of the article
New publications
Preparations
Rabimac
Last reviewed: 23.04.2024
All iLive content is medically reviewed or fact checked to ensure as much factual accuracy as possible.
We have strict sourcing guidelines and only link to reputable media sites, academic research institutions and, whenever possible, medically peer reviewed studies. Note that the numbers in parentheses ([1], [2], etc.) are clickable links to these studies.
If you feel that any of our content is inaccurate, out-of-date, or otherwise questionable, please select it and press Ctrl + Enter.
Rabimak is a medicinal product suppressing the production of hydrochloric acid in the stomach cavity. Consider the indications for use, dosage and possible side effects.
The drug is prescribed for the treatment of acid-dependent diseases, as it affects the metabolism and digestive system. The drug has antiulcer properties and is used to treat gastroesophageal reflux and peptic ulcer. Produced in India, by Macleods Pharmaceuticals Co., Ltd.
Rabimak is released only on medical prescription.
Indications Rabimac
Indications for the use of Rabimac are based on the pharmacological properties of the proton pump inhibitors to which this agent belongs. The international name is rabeprazole. Tablets are prescribed for the treatment and prevention of such diseases as:
- Duodenal ulcer
- Zollinger-Ellison Syndrome
- Eradication of Helicobacter pylori (in combination with other atibacterial agents)
- Stomach ulcer
- Not ulcerative indigestion
- Gastroesophageal reflux disease
- Chronic gastritis (in the stage of exacerbation).
Release form
The form of release - tablets, covered with a shell, enteric-soluble. Basic physical and chemical properties: tablets yellow (10 mg) and reddish brown (20 mg), round, with a notch on one side, biconvex. One package contains 2-3 strips in a carton box, in each strip of 7-10 tablets.
The active substance is rabeprazole. As auxiliary components such components are used: hydroxypropylmethylcellulose, magnesium oxide, methacrylic acid copolymer, hydroxypropyl cellulose, mannitol, magnesium stearate, iron oxide yellow (for tablets 10 mg), iron oxide red (for tablets 20 mg) and others.
Pharmacodynamics
Pharmacodynamics Rabimak is a mechanism of action of active components. The drug belongs to the class of antisecretory compounds, has no anticholinergic properties and does not belong to the host-H2 receptor antagonists. Oppresses the secretion of gastric acid by inhibiting the enzyme H + / K + -ATPase in parietal cells of the stomach. This enzyme system belongs to proton pumps, so Rabimak in this category. The active substance blocks the production of hydrochloric acid at the final stage and is transformed into an active sulfonamide form.
After 1-3 hours after administration, there is an antisecretory effect that suppresses the two functions of acid secretion. The effectiveness of oppression of secretion is enhanced with a daily intake of 1 tablet, but a stable effect is achieved 3 days after the start of admission. After the completion of the course of treatment, the secretory activity is restored within 2-3 days.
Pharmacokinetics
The pharmacokinetics of Rabimac are the processes of absorption, metabolism and excretion. Since the tablets are coated with an enteric coating, they are quickly and completely absorbed in the intestine. The maximum concentration in the blood plasma begins 3-4 hours (at a dosage of 20 mg). Bioavailability for oral administration is about 52% because of the metabolism of the first passage. With repeated use of the drug, bioavailability does not increase.
The half-life from the plasma takes 1-2 hours, and the total clearance is 283 ± 98 ml / min. Eating does not affect the absorption process. Binding to plasma proteins - 97%. About 90% is excreted by the kidneys in the form of metabolites: thioether (M1) and carboxylic acid (M6). The remaining 10% are excreted with feces.
Dosing and administration
The method of administration and dose depend on the indications for the use of the drug and the doctor's recommendations. For the treatment of peptic ulcer and peptic ulcer of the stomach, patients are prescribed 20 mg once a day (if necessary, the dosage is increased to 40 mg, that is, 20 mg in the morning and in the evening). Duration of treatment is from 2 to 8 weeks, with maintenance therapy up to 12 months.
For non-ulcer dyspepsia, 40 mg once a day for 2-3 weeks is used. For the eradication of H. Glori, a complex therapy regimen with effective antibiotics is used. Rabimak take 20 mg twice a day with other drugs. To treat the syndrome Zollinger-Ellison can use a dosage of 20 to 120 mg per day, the course of treatment is from 2-8 weeks. Chronic gastritis is treated with 40 mg once a day for 2-4 weeks. Tablets are not recommended to chew or grind, take in the morning before eating.
[9]
Use Rabimac during pregnancy
Safety of use of Rabimac during pregnancy is not confirmed. According to the experiments, the drug can penetrate the placental barrier, so it is not recommended to use it in the treatment of expectant mothers. Rabeprazole can penetrate into breast milk, so when using it, it is necessary to stop lactation.
According to the profile of side effects of the drug, it is not recommended for use when working with potentially dangerous mechanisms or when driving vehicles. If the tablets are the cause of increased drowsiness or dermatological manifestations, it is necessary to stop taking them and consult a doctor to choose a counterparty with a safer mechanism of action.
Contraindications
Contraindications to the use of Rabimac is an individual intolerance of the active substance - rabeprazole or other components of the medication. Tablets are not used for hypersensitivity to substituted benzimidazoles.
The period of pregnancy and lactation, are also contraindications to the use of the drug. The agent is not prescribed to children, as there is no reliable information about its safety for patients of this age group.
Side effects Rabimac
Side effects of RABIMAK are rare, since the drug is well tolerated. If this occurs, it has a minor, that is, a mild symptomatology. More often side effects are manifested by the digestive system - these are abdominal pain, flatulence, nausea and vomiting, belching, diarrhea, or constipation. In rare cases, dry mouth, stomatitis, a violation of taste sensations and increased activity of liver enzymes are possible.
In some cases, violations of the hematopoiesis system, that is, thrombocytopenia and leukopenia. Patients may experience symptoms such as headaches and dizziness, drowsiness, depression, and arousal. In rare cases, allergic reactions occur, that is, itching, rash, bronchospasm, or angioedema. Other side effects: back and chest pain, calf muscle cramps, urinary tract infection, pharyngitis, flu-like syndrome.
[8]
Overdose
Overdosing occurs when the doctor's recommendations for the use of the drug are not observed. Most often these are headaches, drowsiness, nausea and vomiting, dizziness, dry mouth and increased sweating. There is no specific antidote, so symptomatic therapy and supportive treatment are used to eliminate overdose.
To avoid side effects, before starting the drug should be eliminated the presence of malignant neoplasms of the gastrointestinal tract. If tablets are prescribed to patients with severe impairment of liver and kidney function, then medical supervision is required in the early stages of therapy.
Interactions with other drugs
The interaction of Rabimac with other drugs is possible if the absorption of other drugs depends on the pH of the gastric contents. This is due to the fact that rabeprazole is metabolized by enzymes (cytochrome P-450 system (CYP450)), like other inhibitors of the proton pump, causes a prolonged decline in the production of hydrochloric acid.
The drug causes a significant decrease in the concentration of ketoconazole and an increase in the concentration of digoxin. Therefore, patients who use these drugs at the same time as Rabimak, need to be monitored by the doctor for timely dosage adjustment.
Storage conditions
The storage conditions of RABIMAK are indicated in the drug instructions. The medicine should be kept in a dry place, protected from direct sunlight and out of reach of children. Recommended storage temperature is 25 ° C.
If the storage rules are not observed, the drug can change its physico-chemical properties. In this case, the medicine must not be taken and should be disposed of.
Shelf life
Shelf life is 24 months from the date of issue. At the end of this period, the medicine should be discarded. Since the use of an overdue drug can lead to uncontrolled side effects.
Attention!
To simplify the perception of information, this instruction for use of the drug "Rabimac" translated and presented in a special form on the basis of the official instructions for medical use of the drug. Before use read the annotation that came directly to medicines.
Description provided for informational purposes and is not a guide to self-healing. The need for this drug, the purpose of the treatment regimen, methods and dose of the drug is determined solely by the attending physician. Self-medication is dangerous for your health.